Radar Therapeutics
Ribonucleic acid sensing technology for therapies that identify and eliminate pathogenic cells based on their genetic activity.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | $13.4m | Seed | |
| Total Funding | 000k | ||
Related Content
Radar Therapeutics is a biotechnology company that develops programmable precision therapeutics. The company's technology is based on ribonucleic acid (RNA) sensing, which allows for the creation of therapies that can identify and target pathogenic cells based on their specific transcriptional signatures or genetic activity. This approach utilizes messenger RNA (mRNA) to create smart programmable medicines.
The company, founded in 2022, recently secured $13.4 million in an oversubscribed seed financing round. This funding is intended to advance the development of its platform and pipeline of therapeutic candidates. The technology has the potential to address a wide range of diseases by precisely targeting unhealthy cells while leaving healthy ones untouched. The business model likely involves partnerships or licensing agreements with larger pharmaceutical firms to bring these treatments through clinical trials and to the market.
Keywords: RNA sensing, precision therapeutics, mRNA technology, pathogenic cells, transcriptional signatures, programmable medicine, biotechnology, seed funding, genetic activity, targeted therapy